More Than Just Supply and Demand
Unlike consumer goods, the price of a medical device like a coronary stent or an MRI machine is not set by a simple free market. Instead, it is the end result of a complex equation involving national healthcare systems, regulatory approvals, and reimbursement
policies. The price in one country, such as the United States, often reflects assumptions about its specific healthcare structure, including insurance reimbursement rates and the purchasing power of large hospital groups. These conditions are rarely the same elsewhere. A device's price in Germany, for example, might be lower due to different government reimbursement schemes, while in India, it could be influenced by government-imposed price caps.
The Global Regulatory Maze
Before a medical device can be sold, it must gain approval from a country's regulatory authority. These processes vary significantly, creating a major cost and time barrier for manufacturers. The U.S. Food and Drug Administration (FDA) has a notoriously stringent and data-heavy process, while the European Union uses a system of 'notified bodies' under its Medical Device Regulation (MDR). India's Central Drugs Standard Control Organisation (CDSCO) has its own evolving framework. Complying with these disparate requirements—which cover everything from clinical trial data to labelling—forces manufacturers to spend significant resources on regulatory compliance for each market they enter, a cost that is inevitably passed on to buyers. Efforts to harmonise these regulations globally, through bodies like the International Medical Device Regulators Forum (IMDRF), have made progress but face hurdles due to differing national priorities and systems.
Who Decides the Final Price?
Once a device is approved, its final price is determined by the local pricing environment. In India, the National Pharmaceutical Pricing Authority (NPPA) has the power to set ceiling prices for 'scheduled' essential devices like certain stents and knee implants to ensure affordability. For 'non-scheduled' devices, the NPPA restricts manufacturers from increasing the Maximum Retail Price (MRP) by more than 10% annually. This contrasts sharply with other markets. The U.S. relies more on confidential negotiations between manufacturers and powerful hospital buying groups. In Europe, prices are heavily influenced by national health insurance reimbursement rates. This patchwork of pricing mechanisms means a manufacturer cannot apply a single global pricing strategy, further complicating trade discussions.
Domestic Industry vs. Foreign Imports
A major point of contention in trade talks is the clash between promoting local industry and providing access to foreign technology. India's 'Make in India' initiative is designed to reduce the country's heavy reliance on imported medical devices, which currently stands at over 70%. Policies like the Production-Linked Incentive (PLI) schemes and high import tariffs are intended to encourage domestic manufacturing. While these policies aim to foster self-reliance and protect against supply chain disruptions, they are often viewed as protectionist measures by trade partners like the U.S., whose delegates push for lower tariffs and fewer barriers to entry for their high-end medical technology. This creates a fundamental deadlock: India wants to build its domestic capabilities, while exporting nations want unfettered access to India's vast market.
The Hidden Costs of Innovation
Trade delegates are often baffled by high prices even after accounting for tariffs. The reason is that the sticker price includes massive, sunk costs that manufacturers must recoup. These include years of expensive research and development, extensive clinical trials to prove safety and efficacy for regulators like the FDA, and ongoing post-market surveillance. Furthermore, there are significant costs associated with international distribution, including freight, customs, local clinical training, and warranty support. These hidden costs, combined with excessive markups by distributors and hospitals at the local level—sometimes reaching over 2,000% in certain cases—mean that even if import duties were eliminated, the final price to the patient would remain stubbornly high.
